FDA Accepts New Drug Application For Cancer Treatment, Azedra

The FDA has accepted for review the New Drug Application (NDA) for Azedra in patients with malignant, recurrent and/or unresectable pheochromocytoma and paraganglioma, which are rare neuroendocrine tumors.